Scholarlink

<p>Vasculogenic mimicry (VM) in breast cancer is recognized as an important non-endothelium-dependent vascular mechanism that promotes tumor invasiveness, survival, and metastatic potential; however, effective and specific intervention strategies remain limited. In this study, we innovatively constructed a nanodelivery system based on hybrid membranes derived from bacterial outer membrane vesicles and breast cancer cell membranes, termed mTOMV, and loaded it with the natural flavonoid isoliquiritigenin (ISL) to enhance targeted antitumor activity. ISL@mTOMV nanoparticles exhibited a uniform spherical morphology, favorable stability, and good biocompatibility. In vitro experiments demonstrated that ISL@mTOMV significantly inhibited the proliferation, migration, and invasion of MDA-MB-231 and MCF-7 breast cancer cells, while promoting tumor cell apoptosis. Mechanistically, ISL@mTOMV markedly reduced the expression of ACLY, H3K27ac, and SMAD5 and suppressed the activity of the TGF-β/SMAD signaling pathway. In vivo experiments further confirmed that ISL@mTOMV inhibited ACLY-mediated H3K27 acetylation, attenuated SMAD5 transcriptional activation, and blocked TGF-β/SMAD signaling, thereby significantly suppressing VM formation in breast cancer. Collectively, this study proposes a highly biocompatible and tumor-targeted nanotherapeutic strategy, providing a new technical approach and potential translational value for VM intervention in breast cancer.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

ISL@mTOMV nanoparticles: a promising approach for VM-targeted therapy in breast cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月1日

查看全文
  • Chengxiao Fu,
  • Zhimin Li,
  • Bowen Tang,
  • Zhongxiang Fan,
  • Yongmei Luo,
  • Xinyu Yi,
  • Bing Shu,
  • Ziliang Liu,
  • Baohong Jiang,
  • Yuehua Li

摘要

Vasculogenic mimicry (VM) in breast cancer is recognized as an important non-endothelium-dependent vascular mechanism that promotes tumor invasiveness, survival, and metastatic potential; however, effective and specific intervention strategies remain limited. In this study, we innovatively constructed a nanodelivery system based on hybrid membranes derived from bacterial outer membrane vesicles and breast cancer cell membranes, termed mTOMV, and loaded it with the natural flavonoid isoliquiritigenin (ISL) to enhance targeted antitumor activity. ISL@mTOMV nanoparticles exhibited a uniform spherical morphology, favorable stability, and good biocompatibility. In vitro experiments demonstrated that ISL@mTOMV significantly inhibited the proliferation, migration, and invasion of MDA-MB-231 and MCF-7 breast cancer cells, while promoting tumor cell apoptosis. Mechanistically, ISL@mTOMV markedly reduced the expression of ACLY, H3K27ac, and SMAD5 and suppressed the activity of the TGF-β/SMAD signaling pathway. In vivo experiments further confirmed that ISL@mTOMV inhibited ACLY-mediated H3K27 acetylation, attenuated SMAD5 transcriptional activation, and blocked TGF-β/SMAD signaling, thereby significantly suppressing VM formation in breast cancer. Collectively, this study proposes a highly biocompatible and tumor-targeted nanotherapeutic strategy, providing a new technical approach and potential translational value for VM intervention in breast cancer.

Graphical abstract